NOTE PURCHASE AGREEMENTNote Purchase Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is dated as of February __, 2017, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”).
AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC.Promissory Note • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this “Amendment”), dated as of January 22, 2017, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company” or the “Borrower”), and the undersigned holders (each, a “Holder” and, collectively, the “Holders”). The Company and the Holders are sometimes referred to individually as “Party” and collectively as the “Parties”.
SECURITY AGREEMENTSecurity Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS SECURITY AGREEMENT is entered into as of February __, 2016 (the “Security Agreement”), by and between the undersigned creditors (“Creditors”), and FLUOROPHARMA MEDICAL, INC., a Nevada corporation, located at 8 Hillside Avenue, Suite 108, Montclair, NJ 07042 (the “Borrower”).
INTERCREDITOR AGREEMENTIntercreditor Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS INTERCREDITOR AGREEMENT (the “Agreement”) is dated as of February __, 2017, and is between “Agents” _____________, with an address of _____________________, ________, and __________, with an address of _____________________, ________, and “Participant” or “Participants” on Schedule I attached hereto, with their address set forth opposite their names.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
This Registration Rights Agreement, dated as of February __, 2017, is by and among FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and those investors set forth on Schedule A to this Agreement (the “Investors”). The Company and the Investors may be collectively referred to as the “Parties.”
